Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Arca Biopharma Inc (ABIO)

Arca Biopharma Inc (ABIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,817
  • Shares Outstanding, K 14,507
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,340 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta 0.91
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.07
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.50
  • Most Recent Earnings $-0.18 on 08/01/24
  • Next Earnings Date 10/16/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.81 +32.60%
on 08/29/24
4.36 -44.95%
on 08/23/24
-0.60 (-20.00%)
since 07/30/24
3-Month
1.81 +32.60%
on 08/29/24
4.36 -44.95%
on 08/23/24
-1.07 (-30.84%)
since 05/30/24
52-Week
1.56 +53.85%
on 01/19/24
4.49 -46.55%
on 05/17/24
+0.34 (+16.51%)
since 08/29/23

Most Recent Stories

More News
ARCA biopharma Announces Second Quarter 2022 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options ...

ABIO : 28.80 (-4.00%)
Emerson Helping Albioma Become a Fully Renewable Energy Provider

Global technology and software company Emerson (NYSE: EMR) has been selected by Albioma (PAR: ABIO), a French independent energy provider, to help transition its coal-fired Bois Rouge plant to 100% renewable...

ABIO : 28.80 (-4.00%)
EMR : 126.39 (+0.13%)
Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of...

ABIO : 28.80 (-4.00%)
CPC Clinical Research Announces Dr. Connie Hess Receives Paul Dudley White Award For rNAPc2 in COVID 19 Presentation at the American Heart Association Vascular Discovery Scientific Sessions

- Dr. Hess was selected as the recipient of an American Heart Association 2022 Paul Dudley White International Scholar Award, which is presented to the primary author of the highest ranked abstract submitted...

ABIO : 28.80 (-4.00%)
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann &...

ABIO : 28.80 (-4.00%)
ARCA biopharma Announces First Quarter 2022 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options ...

ABIO : 28.80 (-4.00%)
ARCA biopharma Establishes Special Committee of the Board of Directors

WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine...

ABIO : 28.80 (-4.00%)
ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial

For the entire cohort of COVID-19 hospitalized patients, the pooled lower and higher rNAPc2 dose groups demonstrated a reduction compared to baseline in...

ABIO : 28.80 (-4.00%)
ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update

Topline data from Phase 2b ASPEN-COVID-19 clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the last week of March...

ABIO : 28.80 (-4.00%)
Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF)In a Phase 2B clinical...

ABIO : 28.80 (-4.00%)

Business Summary

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular...

See More

Key Turning Points

3rd Resistance Point 2.76
2nd Resistance Point 2.61
1st Resistance Point 2.51
Last Price 28.80
1st Support Level 2.26
2nd Support Level 2.11
3rd Support Level 2.01

See More

Last Price 28.80
52-Week High 4.49
Fibonacci 61.8% 3.37
Fibonacci 50% 3.02
Fibonacci 38.2% 2.68
52-Week Low 1.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar